First-line Intraperitoneal Cisplatin and Etoposide Chemotherapy for Ovarian Cancer

Inclusion Criteria: * Age ≥18 years to ≤ 75 years. * Epithelial ovarian cancer with pathology confirmed stage IIIc or IV, expect for lymph node metastasis alone * Optimal cytoreductive surgery, including hysterectomy, bilateral salpinges-oophorectomy, omentectomy, and resection of all metastatic lesions, with a residual disease no more than 1cm * Available to receive intraperitoneal chemotherapy 5-10 days postoperative, or no more than postoperative 14 days for those with bowel resection. * ECOG performance 0-2. * No more than 3 cycles of chemotherapy prior to surgery. * Laboratory testing within 7 days of registration: hematopoietic: absolute neutrophil count greater than 1,500/mm3; Platelet count greater than 100,000/mm3. Hepatic: bilirubin less than 1.25 times upper limit of normal (ULN); Bilirubin \< 2.0, SGPT less than 2 times ULN. Renal: creatinine less than 1.6 mg/dL, OR creatinine clearance greater than 40 mL/min. * Comply with intraperitoneal chemotherapy and follow-up. * Written informed consent. Exclusion Criteria: * Low-malignant potential ovarian tumor. * Laboratory testing insufficiency. Hemoglobin \< 10 g/dL. Renal insufficiency with serum creatinine \> 1.6. * Bone marrow dysfunction: absolute neutrophil count less than 1,500/mm3; Platelet count less than 80,000/mm3. * Active infection. * Clinically significant gastrointestinal abnormalities. * Active coronary artery disease, cerebrovascular disease, restrictive or obstructive pulmonary disease, or congestive heart failure. * Other condition that could interfere with provision of informed consent, compliance to study procedures, or follow-up. * Prior invasive malignancies within the last 5 years showing activity of disease.